Ocular manifestations in a patient with de novo Fabry disease |
Lee, You Hyun
(Department of Ophthalmology, Keimyung University School of Medicine)
Shim, Kyu Young (Department of Ophthalmology, Keimyung University School of Medicine) Park, Sung Bae (Department of Internal Medicine, Keimyung University School of Medicine) Kim, Yu Cheol (Department of Ophthalmology, Keimyung University School of Medicine) |
1 | Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 2013;28:505-17. DOI |
2 | Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab 2012;107:267-75. DOI |
3 | Iemolo F, Pizzo F, Albeggiani G, Zizzo C, Colomba P, Scalia S, et al. De novo mutation in a male patient with Fabry disease: a case report. BMC Res Notes 2014;7:11. DOI |
4 | Samiy N. Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 2008;53:416-23. DOI |
5 | Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979;97:671-6. DOI |
6 | Lee HG, Kim MJ, Choi CY, Tchah H. Fabry disease in a family: four patients and five carriers. J Korean Ophthalmol Soc 2006;47:1496-501. Korean. |
7 | Pisani A, Daniele A, Di Domenico C, Nigro E, Salvatore F, Riccio E. Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. BMC Res Notes 2015;8:711. DOI |
8 | Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-38. DOI |